MediWound Ltd. (NASDAQ:MDWD) communicated second quarter financial results before market open today.
The company disclosed income of $ 12.72 million or $ 0.47 per share, compared with loss of $ 4.17 million or $ 0.15 per share, a year ago period.
MDWD recorded revenue that grew 1,914.56 percent to $ 20.75 million from $ 1.03 million in the same quarter last year
The consensus estimates are loss of $ 0.03 per share from $ 4.45 million in revenue.
Analysts estimates are from Thomson Reuters, exclude one time gain or loss.
Sharon Malka, Chief Executive Officer, said, We continued being active in the second quarter and thereafter, with several significant milestones including signing commercial license and supply agreements with Vericel for NexoBrid in North America and confirming with the FDA in a pre-BLA meeting our BLA submission plans, which puts us on track to file a BLA for NexoBrid in the second quarter of 2020 and a clear path to the U.S. commercial market